Jose Lutzky MD FACP

Oncology•Miami, FL

Melanoma

Director, Cutaneous Oncology - Sylvester Comprehensive Cancer Center.

Join to View Full Profile

1475 NW 14th AveMiami, FL 33125
Phone+1 305-689-6500
Fax+1 305-689-6565

Summary

Jose Lutzky, M.D., is a triple board-certified hematologist and oncologist at Sylvester Comprehensive Cancer Center. At Sylvester, Dr. Lutzky works as part of a multidisciplinary team of cancer experts and researchers. He earned his medical degree from Universida de Federal do Rio Grande do Sul. Dr. Lutzky is fluent in Spanish and Portuguese.

Clinical Expertise

Melanoma and cutaneous malignancies

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1985 - 1988
Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 1982 - 1985
Federal University of Rio Grande do Sul School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1989 - 2027
FL State Medical License 1984 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2020
America's Top Doctors for Cancer Castle Connolly, 2020
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma Start of enrollment: 2007 May 01
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
ACTIVE_NOT_RECRUITING
PHASE3
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma Start of enrollment: 2006 Feb 01
Completed
Phase 2
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System Start of enrollment: 2009 Nov 01
Completed
Phase 2
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Start of enrollment: 2010 Jun 01
Completed
Phase 2
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) Start of enrollment: 2011 Dec 29
Completed
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) Start of enrollment: 2012 Jul 03
Completed
Phase 2
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Start of enrollment: 2018 Jan 29
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.
Rino S Seedor, Andrew E Aplin, Corine Bertolotto, Richard D Carvajal, Nigel Deacon
Pigment Cell & Melanoma Research. 2025-01-01
Is primary breast melanoma a true pathological entity? The argument against it.
Alexis R Narvaez-Rojas, Samantha Linhares, Shaina Sedighim, Kyle Daniel Klingbeil, Clara Milikowski
Heliyon. 2024-09-30

Journal Articles

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma
Igor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology

Authored Content

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

Press Mentions

Sylvester Cancer Tip Sheet - March 2025March 21st, 2025
Sylvester Researchers Study Quality of Life During Immunotherapy TreatmentMarch 12th, 2025
Northwest Biotherapeutics: Data Is Done, Just Wait for ApprovalNovember 23rd, 2022
Join now to see all